Clinical trials: Limited Stage
HER2-positive Early-stage Breast Cancer
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
This is an open-label phase 2 study to evaluate the pCR rate in patients diagnosed with HER2 positive breast cancer treated on an adaptive clinical trial design.
- Trial name
- EUREKA (NCT07402473)
- Testing
- Trastuzumab, Pertuzumab, Docetaxel
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Papillary Thyroid Carcinoma
Safety of Endoscopic Thyroidectomy Via Retro-Auricular Single-Site Approach, Transoral Approach and Transareola
The goal of this retrospective study is to compare the safety and efficiacy of endoscopic thyroidectomy via retro-auricular single-site approach, transoral endoscopic thyroidectomy vestibular approach and transareola approach.
- Trial name
- NCT05760690
- Testing
- Retro-Auricular Single-Site Endoscopic Thyroidectomy, Transoral Endoscopic Thyroidectomy Vestibular Approach, Transareola Endoscopic Thyroidectomy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-sen University
Breast Cancer Female, Early-Stage Breast Cancer
Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients
This study is designed to compare the effectiveness of intradermal injection and subcutaneous injection with methylene blue for early-stage breast cancer patients who need sentinel lymph node biopsy.
- Conditions
- Breast Cancer Female, Early-Stage Breast Cancer, Sentinel Lymph Node
- Trial name
- NCT02982148
- Testing
- methylene blue intradermal injection, methylene blue subcutaneous injection
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer
RATIONALE: The combination of anti-angiogenic targeted therapy with neoadjuvant chemotherapy has been shown to further improve the pathologic response rate for HER2-negative breast cancer patients.
- Trial name
- APP (NCT03982485)
- Testing
- Apatinib, Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 196 people
- Sponsor
- RenJi Hospital
Non-small Cell Lung Cancer (NSCLC)
The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer
The primary objective of this study is to determine whether circulating tumor cells (CTCs) can be used as a non-invasive means of confirming pathologic diagnosis in early-stage (Stage I) non-small cell lung cancer (NSCLC).
- Trial name
- NCT02380196
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Communication and Intimacy-Enhancing Therapy for Men With Early Stage Prostate Cancer and Their Partners
RATIONALE: Participating in a therapy program may enhance communication and intimacy between men with prostate cancer and their partners.
- Conditions
- Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Sexual Dysfunction and Infertility, Sexuality and Reproductive Issues
- Trial name
- NCT00503646
- Testing
- communication intervention, counseling intervention, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colon Cancer Screening, Healthy Person
PROgastrine COlon DEpistage
Dosage of progastrin in asymptomatic person participating in colon cancer screening
- Trial name
- NCT03775473
- Testing
- progastrin
- Where
- France
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- ECS-Progastrin SA
Early-stage Breast Cancer
Cardioprotective Effect of Acute Exercise in Breast Cancer Patients
Cardiotoxicity is one of the most significant adverse effects in breast cancer patients treated with anthracyclines (a type of chemotherapy), so we propose to determine whether acute training (i.e., 24h before each chemotherapy…
- Trial name
- CardioProtEx (NCT05467111)
- Testing
- Acute Exercise
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Technical University of Madrid
Endometrial Cancer
Signatera Assessment in Early-Stage Endometrial Cancer
The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer.
- Trial name
- SIGNAL-EMC 101 (NCT07339384)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Where
- 12 sites in United States
- Volunteers
- 1,010 people
- Sponsor
- Natera, Inc.
Non-small Cell Lung Cancer
Multiomics Tumor Evolution Model of NSCLC
The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be…
- Trial name
- NCT05352035
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Peking University People's Hospital
Breast Cancer, Early Stage
Ablation Compare With Surgery for Early Breast Cancer
Breast-conserving surgery has been widely used in clinical practice, but surgical incisions still impact postoperative patient satisfaction with breast appearance.
- Conditions
- Breast Cancer, Early Stage, Hormone Receptor Positive, Ablation
- Trial name
- NCT07484087
- Testing
- breast conserving surgery, cryo-thermal ablation
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Peking University People's Hospital
Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors
The purpose of this randomized clinical trial is to learn if 'complex' cancer patients who receive care guided by a health system intervention, Primary Care Connect (PC2) have their risks of cardiovascular disease (CVD) managed…
- Conditions
- Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma)
- Trial name
- ACCESS-PC (NCT06834204)
- Testing
- PC2: Primary Care Connect
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Rutgers, The State University of New Jersey
Supraglottic Squamous Cell Carcinoma, Early Stage (T1-T2, N0-N1,M0)
Treatment of Early Supraglottic Squamous Cell Carcinoma With Advance Technologies
In this project, the investigators will realize an observational, prospective, multicentric and international clinical trial, to objectively compare patients with SSCC according to 3 arms of treatment: Arm 1: Radiotherapy ±…
- Trial name
- SUPRA-QoL (NCT05611515)
- Testing
- TORS
- Where
- Belgium
- Volunteers
- 108 people
- Sponsor
- Centre Hospitalier Universitaire UCLouvain Namur
Breast Cancer, Lung Cancer
T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment. It may also help the study of cancer in the future.
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT00433407
- Testing
- trastuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Neoplasm, Early-Stage Breast Cancer
Testing of the Cancer Thriving and Surviving Breast Cancer Program
The adjusted Cancer Thriving and Surviving Program (CTS) for women with breast cancer living in Switzerland (CTS-BC-CH) is a course of 7 weekly sessions of 2.5 - 3 hours led by trained peer-leaders (women with breast cancer…
- Conditions
- Breast Neoplasm, Early-Stage Breast Cancer, Self-Management, Intervention
- Trial name
- COSS (NCT03651921)
- Testing
- CTS-BC-CH
- Where
- 2 sites in Switzerland
- Volunteers
- 39 people
- Sponsor
- Manuela Eicher
Recurrent Hepatocellular Carcinoma
Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC
This is a randomized, controlled, phase 2 study to assess the efficacy and safety of ablation followed by tislelizumab versus ablation alone in patients with early recurrent hepatocellular carcinoma.
- Trial name
- NCT04663035
- Testing
- Tislelizumab, Ablation
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Ming Zhao
Breast Cancer
Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer
The purpose of this study is to evaluate the rate of early and intermediate toxicity related to the AccuBoost System for delivery of APBI in women with resected, early stage breast cancer.
- Trial name
- NCT01463007
- Testing
- Accelerated partial breast irradiation, Extended Follow up
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jaroslaw Hepel
Predictive Cancer Model, Lung Cancer
CT-based Radiomic Algorithm for Assisting Surgery Decision and Predicting Immunotherapy Response of NSCLC
The purpose of this study was to investigate whether the combined radiomic model based on radiomic features extracted from focus and perifocal area (5mm) can effectively improve prediction performance of distinguishing…
- Conditions
- Predictive Cancer Model, Lung Cancer, Preinvasive Adenocarcinoma
- Trial name
- TOP-RLC (NCT04452058)
- Testing
- Radiomic Algorithm
- Where
- 3 sites in China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast Cancer
This is a non-randomized, Phase II study. Efficacy is not a primary endpoint in this study; however, progression-free survival will be followed and determined for the patients in this study.
- Trial name
- NCT00629499
- Testing
- nab paclitaxel, Cyclophosphamide, Trastuzumab
- Where
- 10 sites in United States
- Volunteers
- 63 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Evaluating Whether Integration of Prognostic and Predictive Algorithms Into Routine Clinical Practice Effect Whether Oncologists Order Multigene Assays in Patients With Early Stage Breast Cancer
A broad range of prognostic and predictive tools are available for patients with newly diagnosed early stage breast cancer. These range from free and publicly available mathematical algorithms, through to expensive genomic tests.
- Trial name
- REaCT-Algorith (NCT04131933)
- Where
- 6 sites in Canada
- Volunteers
- 602 people
- Sponsor
- Ottawa Hospital Research Institute